Selective Antimicrobial Compounds Inhibiting Pathogens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimicrobial compounds often inhibit both pathogenic and commensal microbes, leading to resistance issues and undesirable side effects due to the need for higher doses.
Innovation Solution
Development of selective antimicrobial compounds with a specific structure that preferentially inhibit pathogenic microbes over commensal microbes, minimizing harm to beneficial microorganisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad spectrum antimicrobial compounds are used to inhibit pathogenic microbes, then antimicrobial efficacy is improved, but commensal microbes are also inhibited causing resistance and side effects
Solution Approach 1:
The patent applies local quality by designing antimicrobial compounds with specific molecular structures (Formulae 1-4) that exhibit different biological activities against different microbe types. The compounds have specific functional groups and structural features that enable selective interaction with pathogenic microbe targets while sparing commensal microbes, achieving localized efficacy against specific pathogens without broad-spectrum inhibition.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as R1-R6 substituents, ring structures (Ar1-Ar6), and linker groups in Formulae 1-4 to optimize selectivity. By adjusting these chemical parameters, the compounds achieve enhanced specificity for pathogenic microbes while maintaining low activity against commensal species, thereby resolving the contradiction between efficacy and selectivity.
2Reliability
If higher doses of antimicrobial treatments are used to overcome resistance, then antimicrobial efficacy is improved, but toxicity and side effects increase
Solution Approach 1:
The compounds exhibit local quality through their molecular design, where specific structural features (Formulae 1-4) create high affinity for pathogenic microbe targets. This localized specificity allows effective inhibition of pathogens at lower concentrations, avoiding the need for high doses that would cause systemic toxicity and side effects.
Solution Approach 2:
The patent introduces a selective molecular intermediary (the compounds of Formulae 1-4) that mediates between the treatment goal and the host organism. These intermediaries selectively bind to pathogenic microbe targets through specific molecular interactions, enabling effective pathogen inhibition while minimizing non-specific effects on host cells and commensal microbes, thus reducing toxicity.
3Ease of operation
If standard antimicrobial courses are used, then treatment simplicity is maintained, but effectiveness decreases due to resistance
Solution Approach 1:
The patent applies parameter changes by developing compounds with optimized molecular parameters (Formulae 1-4) that exhibit enhanced activity against resistant pathogens. These structurally modified compounds maintain straightforward administration protocols while achieving superior effectiveness against resistant strains, resolving the contradiction between treatment simplicity and effectiveness.
Data Source
AI summary
A compound can have a structure of Formula A, or derivative thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combination thereof:wherein ring A is a phenyl, indolyl, naphthyl, or benzothiazolyl; X is S, SO, or SO2; Y is a linker or bond; Z is CH, CR2, or N; Z1 is C or N to form an imidazopyridine; each Z2, Z3, or Z4 is independently CH, CR2, or N; each Z5 or Z6 is C or CH; each R1, R2, and R3 is independently a substituent, and at least one of R1, R2, or R3 is a substituent other than a hydrogen; m is 0, 1, 2, 3, or 4; and n is 0 or a positive integer. The compounds can have specific substituent patterns.